drugset / Trial / NCT02711956

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02711956

Phase 1/2 Completed 75 enrolled Zenith Epigenetics
NaSingle-groupOpen-labelTreatment

Summary

This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.

Timeline

Start
2016-12
Primary completion
2019-11
Completion
2019-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ZEN-3694 Small molecule Oral
Background Enzalutamide Other / unclassified